Max Healthcare Q4 FY26: steady growth, heavy capacity build, and cash that funds it

Max Healthcare closed Q4 FY26 with the kind of operating consistency investors look for in hospital businesses: volumes moved up, revenue followed, and margins held largely steady even as the network staffed up for the next leg of expansion. Network gross revenue rose to ₹ 2,664 Cr, up 10 percent year on year. Network Operating EBITDA came in at ₹ 682 Cr, up 8 percent year on year, while profit after tax for the network increased to ₹ 387 Cr.

The quarter was not only about reported numbers. It also marked a transition point in capacity. Over the past six months, Max Healthcare has rolled out nearly 20 percent additional brownfield capacity across key markets, with another roughly 10 percent expected by year end with the greenfield Gurugram facility. This matters because hospitals do not scale like typical service businesses. Beds and clinician talent need to be in place before revenue arrives. In Q4, the network absorbed higher clinician and manpower costs, but it also generated strong free cash from operations at ₹ 581 Cr, giving the company room to keep investing.

Q4 FY26 performance: growth led by volumes, margins broadly stable

The headline revenue increase was mainly driven by higher occupied bed days, which grew 8 percent year on year. Average occupancy was 75 percent, the same level as last year, indicating that incremental capacity is being added into a system that is still reasonably utilized. ARPOB was ₹ 77.9k, slightly higher than ₹ 77.1k a year ago and unchanged sequentially.

Profitability stayed in a tight band. Operating margin was 26.8 percent versus 27.2 percent in Q4 FY25 and 26.1 percent in Q3 FY26. The near term pressure point was clinician cost. Management highlighted clinician costs rising about 230 bps year on year and about 120 bps quarter on quarter. The driver was deliberate: aggressive hiring to support future growth and capacity expansions. That is a common trade-off in hospital expansions. The cost base moves first, and operating leverage follows as patient volumes ramp up.

One important mix item in the quarter was oncology. Due to discontinuation of select high value patented chemotherapy drugs for institutional patients following new MOU conditionalities, oncology share in IPD revenues fell to 21 percent from 26 percent in Q4 FY25. The company noted that excluding oncology, gross revenue growth was 15 percent year on year and 5 percent quarter on quarter. This helps explain why ARPOB remained stable even as volumes improved.

International patient revenue continued to grow. It was ₹ 227 Cr, up 12 percent year on year, and represented about 9 percent of hospital revenue. This is a meaningful contributor because international cases are typically higher acuity and can support specialty depth, though Max Healthcare did not break out margin impact specifically.

Financial summary

Capacity expansion is now the central operating story

Max Healthcare’s Q4 message was clear: the network is moving through a large, staged capacity addition cycle. In the last 12 months, operational bed capacity reached 4,966 beds, an addition of 412 beds, largely from MSSH Dwarka, Nanavati-Max, MSSH Lucknow and MSSH Mohali. The quarter also saw the operationalisation of new towers, which will shape both utilization and margins over the next few quarters.

Three projects stood out.

At Max Smart Super Specialty Hospital, a 400-bed brownfield tower was commissioned in April 2026. Of these, 156 beds have been handed over to operations, with the rest expected to be progressively handed over in the next quarter. At Mohali, a 160-bed brownfield tower has been fully commissioned and operationalized. At Nanavati-Max, a 280-bed phase 1 tower has operationalized 116 beds, with the remaining expected over the next three months. The larger Nanavati-Max Tower 2 is described as a 553-bed facility, with phase 2 work expected to commence in July 2026.

These projects explain why average length of stay was temporarily higher by 9 percent versus Q4 FY25. When a hospital adds capacity and rebalances departments, ALOS can move up in the short term. Over time, the benefit for investors is scale in key specialties and better case mix. But in early ramp-up, the operational focus is to fill beds, stabilize clinical teams, and improve throughput.

The company also expanded its footprint through acquisition. It consummated the purchase of a controlling stake of 58.28 percent in Kalinga Hospital Ltd. on May 18, 2026. Kalinga operates a 250-bed hospital on a 10-acre land parcel in Bhubaneswar. Management commentary suggested the integration work has already started, with focus on operational upside and an upgrade and expansion plan.

In addition, the Board approved an investment of about ₹ 1,400 Cr for a 712-bed greenfield hospital at Shaheed Path, Lucknow, expected to be commissioned in FY30. The project is large and long-dated, but it signals management’s confidence in demand growth and its willingness to commit capital in chosen markets.

Mix, specialties, and how demand is shaping up

Operational metrics suggest demand remains broad-based. Inpatient volumes in Q4 FY26 were 81,791, up 3.9 percent year on year. Outpatient consults were 9.23 lakh, up 8.1 percent year on year. Digital revenue attributed to online marketing, web-based appointments and lead management was ₹ 838 Cr, or about 31 percent of gross revenue, with website traffic up 39 percent year on year to more than 90 lakh sessions.

Specialty mix shifted mainly due to the oncology change in institutional chemotherapy drugs. Oncology share of gross IP revenue declined to 21.2 percent in Q4 FY26 from 25.7 percent in Q4 FY25. Other specialties either held steady or rose modestly. For instance, neuro sciences increased to 10.5 percent from 9.3 percent, orthopedics to 11.0 percent from 10.0 percent, and gastroenterology to 5.9 percent from 4.7 percent.

Payor profile remained stable. Self pay was 32.8 percent in Q4 FY26, insurance and corporates 36.5 percent, international 9.1 percent, and institutional 21.6 percent. Institutional patient bed share was 35.5 percent, broadly in line with recent quarters.

Regional performance shows Delhi remains the largest market, with Q4 FY26 gross revenue of ₹ 1,378 Cr and 80 percent occupancy on 2,411 operational beds. Uttar Pradesh reported ₹ 539 Cr of gross revenue with 74 percent occupancy on 1,177 beds. Maharashtra grew to ₹ 280 Cr on 595 beds with 67 percent occupancy, reflecting the expansion ramp at Nanavati-Max.

Adjacent businesses: Max Lab and Max at Home add growth vectors

Max Healthcare’s hospital network remains the core earnings driver, but two adjacent businesses showed strong momentum in Q4 FY26.

Max Lab reported revenue of ₹ 52 Cr, up 14 percent year on year and 11 percent quarter on quarter. EBITDA was ₹ 8.6 Cr with an EBITDA margin of 17 percent. The platform’s reach now spans more than 60 cities, with 600 plus collection centres, 830 plus pick-up points, and 53 test processing labs. The number of bills in Q4 FY26 was 952 thousand.

Max at Home reported gross revenue of ₹ 73 Cr, up 30 percent year on year and 8 percent quarter on quarter. The quarter’s growth was driven by physio and rehab, nursing care and attendants, and transactional services like sample collection and medicine delivery.

These businesses are not yet large relative to the hospital P and L, but they add two important qualities: a broader funnel for patient acquisition and a more continuous relationship with patients outside hospital stays.

Cash flows, leverage, and what the quarter says about execution

The strongest signal in Q4 FY26 was cash generation. Free cash from operations was ₹ 581 Cr, up from ₹ 422 Cr a year ago and ₹ 281 Cr in Q3 FY26. During the quarter, ₹ 328 Cr was deployed towards ongoing expansion plans and upgradation of new units, and ₹ 6 Cr was received from ESOP exercises.

Net debt ended March 2026 at ₹ 1,908 Cr. It was lower than ₹ 2,166 Cr at the end of December 2025, even with expansion capex continuing. For FY26, cash from operations was ₹ 1,541 Cr, and the company deployed ₹ 1,627 Cr towards expansion plans and upgradation, plus ₹ 131 Cr for purchase of land at Vaishali and ₹ 146 Cr as dividend distribution. The Board also recommended a dividend of ₹ 2 per share on May 21, 2026, subject to shareholder approval.

This combination, expanding capacity while keeping leverage manageable and paying dividends, only works if operating cash generation remains strong. The company’s operating margins remain healthy, but investors should track two near-term variables: clinician cost intensity during ramp-up, and the pace at which new beds move from commissioned to consistently occupied.

Closing view: a ramp-up year with visible operating levers

Max Healthcare’s Q4 FY26 was less about a single standout number and more about reinforcing a pattern. It delivered its 22nd consecutive quarter of year-on-year growth, with revenue up 10 percent and operating EBITDA up 8 percent. At the same time, it is moving through an unusually heavy phase of brownfield commissioning, with talent already onboarded and operating leverage expected as utilization builds.

For investors, the quarter offers three clean takeaways. First, demand indicators remain stable: occupancy held at 75 percent even as beds increased, and both OP and IP volumes grew. Second, margins are holding up despite higher clinician costs, suggesting discipline in pricing and cost management. Third, cash generation is strong enough to fund expansion, support integration of Kalinga Hospital, and still leave room for shareholder returns.

The next few quarters will likely be about execution in ramp-up rather than headline growth alone. If new towers in Delhi, Mohali, and Mumbai fill up as planned, the network should see operating leverage kick in, which can support both profitability and balance sheet strength while the company builds toward its next greenfield milestones.